Evolution of small cell lung cancer tumor mutation: from molecular mechanisms to novel viewpoints

Guan, Xiaojiao; Bao, Guangyao; Liang, Jie; Yao, Yao; Xiang, Y.; Zhong, Xinwen

doi:10.1016/j.semcancer.2022.03.015

Cited by 4 publications

(3 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple gene mutations have been found in NSCLC patient, including epidermal growth factor receptor (EGFR) ( Zhao D. et al, 2022 ; Castaneda-Gonzalez et al, 2022 ), Kirsten rat sarcoma viral oncogene homolog (KRAS) ( Desage et al, 2022 ; Garcia-Robledo et al, 2022 ), anaplastic lymphoma kinase (ALK) ( Cognigni et al, 2022 ; Xiang et al, 2022 ), Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2) ( Ni and Zhang, 2021 ; Vathiotis et al, 2021 ; Yu X. et al, 2022 ), B-Raf proto-oncogene (BRAF) ( Abdayem and Planchard, 2022 ; Riudavets et al, 2022 ; Sforza et al, 2022 ), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), AKT serine/threonine kinase 1 (AKT1), mitogen-activated protein kinase kinase 1 (MAP2K1) ( Kim and Giaccone, 2018 ; Han et al, 2021 ), c-ros oncogene 1 (ROS1) ( Guaitoli et al, 2021 ; Yu Z. Q. et al, 2022 ), neurotrophic tyrosine receptor kinase (NTRK) ( Liu C. et al, 2022 ; Qin and Patel, 2022 ), and mesenchymal-epithelial transition factor (MET) ( Pao and Girard, 2011 ; Olmedo et al, 2022 ) ( Figure 1 ). In SCLC patients, gene mutations often include retinoblastoma (Rb), TP53, PTEN, FBXW7, VHL mutations ( Cardona et al, 2019 ; Guan et al, 2022 ). In addition, targeted therapy, immunotherapy, antiangiogenic therapy and combination therapy have been used in the clinic for lung cancer patients ( Luo et al, 2021 ; Wang et al, 2021 ; Guo et al, 2022 ) ( Figure 1 ).…”

Section: Introductionmentioning

confidence: 99%

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

Wang

Zhu²,

Yang³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Lung cancer is the common malignant tumor with the highest mortality rate. Lung cancer patients have achieved benefits from immunotherapy, including immune checkpoint inhibitors (ICIs) therapy. Unfortunately, cancer patients acquire adaptive immune resistance, leading to poor prognosis. Tumor microenvironment (TME) has been demonstrated to play a critical role in participating in acquired adaptive immune resistance. TME is associated with molecular heterogeneity of immunotherapy efficacy in lung cancer. In this article, we discuss how immune cell types of TME are correlated with immunotherapy in lung cancer. Moreover, we describe the efficacy of immunotherapy in driven gene mutations in lung cancer, including KRAS, TP53, EGFR, ALK, ROS1, KEAP1, ZFHX3, PTCH1, PAK7, UBE3A, TNF-α, NOTCH, LRP1B, FBXW7, and STK11. We also emphasize that modulation of immune cell types of TME could be a promising strategy for improving adaptive immune resistance in lung cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

Wang

Zhu²,

Yang³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“… 2 It is characterized by high circulating tumor cell, rapid tumor growth, early and extensive metastasis, and the survival time is dismal. 3 , 4 Although chemotherapy and radiotherapy have been the standard treatment for the past few decades, it is extremely vulnerable to drug resistance and recurrence, 5 and no substantial progress has been made in systemic therapy.…”

Section: Introductionmentioning

confidence: 99%

Identification of Immune Subtypes and Candidate mRNA Vaccine Antigens in Small Cell Lung Cancer

et al. 2023

View full text Add to dashboard Cite

Background Immune checkpoint inhibitors (ICIs) have demonstrated promising outcomes in small cell lung cancer (SCLC), but not all patients benefit from it. Thus, developing precise treatments for SCLC is a particularly urgent need. In our study, we constructed a novel phenotype for SCLC based on immune signatures. Methods We clustered patients with SCLC hierarchically in 3 publicly available datasets according to the immune signatures. ESTIMATE and CIBERSORT algorithm were used to evaluate the components of the tumor microenvironment. Moreover, we identified potential mRNA vaccine antigens for patients with SCLC, and qRT-PCR were performed to detect the gene expression. Results We identified 2 SCLC subtypes and named Immunity High (Immunity_H) and Immunity Low (Immunity_L). Meanwhile, we obtained generally consistent results by analyzing different datasets, suggesting that this classification was reliable. Immunity_H contained the higher number of immune cells and a better prognosis compared to Immunity_L. Gene-set enrichment analysis revealed that several immune-related pathways such as cytokine-cytokine receptor interaction, programmed cell death-Ligand 1 expression and programmed cell death-1 checkpoint pathway in cancer were hyperactivated in the Immunity_H. However, most of the pathways enriched in the Immunity_L were not associated with immunity. Furthermore, we identified 5 potential mRNA vaccine antigens of SCLC (NEK2, NOL4, RALYL, SH3GL2, and ZIC2), and they were expressed higher in Immunity_L, it indicated that Immunity_L maybe more suitable for tumor vaccine development. Conclusions SCLC can be divided into Immunity_H and Immunity_L subtypes. Immunity_H may be more suitable for treatment with ICIs. NEK2, NOL4, RALYL, SH3GL2, and ZIC2 may be act as potential antigens for SCLC.

show abstract

“…One field that has seen impressive growth in recent years is immunotherapy, which seeks to rid the body of tumor cells through the artificial augmentation of the human immune system’s natural antitumor abilities ( Chen and Mellman, 2013 ; Vermaelen et al, 2018 ; Brown et al, 2022 ). Tumors are incredibly adaptive due to their lack of regulation on gene replication ( Guan et al, 2022 ), which can result in the development of impressive anti-inflammatory conditioning within the tumor microenvironment (TME) to promote tumor growth and exploit the inhibitory checkpoints that exist to regulate the immune system under normal conditions ( Cassim and Pouyssegur, 2020 ). Because of the immunosuppressive nature of the TME, tumors are often able to eliminate one of the body’s best defenses against tumors: cytotoxic T cells ( Ngiow et al, 2015 ; YeonYeon et al, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Nanoformulation improves antitumor efficacy of MAOI immune checkpoint blockade therapy without causing aggression-related side effects

Brown

Wang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

MAOIs, a well-established class of antidepressant that operate through the inhibition of monoamine oxidase to increase available serotonin, have recently been identified as a surprisingly effective candidate for the circumvention of tumor-induced immune suppression due to their abilities to enhance antitumor T cell activity through autocrine serotonin signaling and depolarize alternatively activated tumor-associated macrophages through a reduction in reactive oxygen species production. However, this impressive class of antidepressants-turned-cancer-drugs can induce aggressive behavioral side effects when administered in immunotherapeutic doses. In this study, we investigated the possibility of avoiding these neurological side effects while simultaneously improving antitumor activity by establishing crosslinked multilamellar liposomal vesicles (cMLVs) containing the MAOI phenelzine (PLZ). Our results showed that cMLV-PLZ treatment increases antitumor efficacy in a B16-OVA mouse melanoma model compared to treatment with free phenelzine. We also found that nanoformulation resulted in the complete elimination of MAOI-related aggression. These findings suggest a promising direction for the future of MAOIs repurposed for cancer immunotherapies.

show abstract

Evolution of small cell lung cancer tumor mutation: from molecular mechanisms to novel viewpoints

Cited by 4 publications

References 78 publications

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

Identification of Immune Subtypes and Candidate mRNA Vaccine Antigens in Small Cell Lung Cancer

Nanoformulation improves antitumor efficacy of MAOI immune checkpoint blockade therapy without causing aggression-related side effects

Contact Info

Product

Resources

About